Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025

Submitted by amarin on Sun, 08/31/2025 - 12:30
Home
News
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic…

-- Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanisms of Action -- DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 31, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted in vitro data assessing the effects of EPA on lipoprotein(a) [Lp(a)] oxidation

New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

Submitted by amarin on Sat, 08/30/2025 - 12:30
Home
News
New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZ…
-- 2025 ESC/EAS Dyslipidemia Guideline Focused Update Reaffirms High Dose Icosapent Ethyl as Class IIA Recommended Therapy in High-Risk or Very High-Risk Patients Based on REDUCE-IT -- DUBLIN and BRIDGEWATER, N.J., Aug. 30, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025

Submitted by amarin on Mon, 08/25/2025 - 12:00
Home
News
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the Eu…
DUBLIN and BRIDGEWATER, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced upcoming presentations at the European Society of Cardiology (ESC) Congress 2025, August 29 th -September 1 st , in Madrid, Spain, where new data will further illuminate the

Amarin Reports Second Quarter 2025 Financial Results

Submitted by amarin on Wed, 07/30/2025 - 11:00
Home
News
Amarin Reports Second Quarter 2025 Financial Results
-- European Partnership with Recordati Established to Maximize VAZKEPA ® in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12 Months --  -- Q2 2025 Financial Performance Reflects Incremental Progress for VASCEPA ® /VAZKEPA ® in

Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025

Submitted by amarin on Wed, 07/23/2025 - 11:30
Home
News
Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call…
DUBLIN and BRIDGEWATER, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2025 results and recent strategic
Subscribe to